手术治疗非小细胞肺癌伴癌性胸膜炎的临床分析（论文资料）.docVIP

KKME---专业医学搜索引擎/ 手术治疗非小细胞肺癌伴癌性胸膜炎的临床分析 　　作者：孙楠 作者单位：中国医科大学附属第一医院胸外科; 　　【摘要】 目的 探索治疗非小细胞肺癌伴癌性胸膜炎的新方法以提高生存期及生存质量。方法 对20例非小细胞肺癌伴癌性胸膜炎的患者采用原发病变切除、氩气刀电烧胸膜转移结节、温热低渗cisplatin溶液胸腔灌洗的外科疗法。结果 20例患者无手术死亡，无严重不可逆的化疗毒副反应和手术并发症发生，恶性胸水治疗显效率100%，无胸水再发生存期22个月，中位生存期23个月，平均生存期19个月。结论 本治疗方法安全，可明显提高非小细胞肺癌伴癌性胸膜炎患者的生存期和生存质量，值得在临床进一步探讨。 　　【关键词】 手术 非小细胞肺癌 癌性胸膜炎 顺铂 　　Clinic Analysis of Surgical Treatment for Non-small Cell Lung Cancer 　　with Carcinomatous PleuritisSUN Nan1, ZHAO Xiang2, LIU Shun-shou2，ZHANG Lin1 　　1.Department of Thoracic Surgery, the First Clinical College, China Medical University, 　　Shenyang 110001 China; 　　2.Department 2 of Thoracic Surgery, Liaoning Cancer Hospital Institute, Shenyang 110042 China 　　【Abstract】 Objective To lengthen the survival time and improve the QOL of the patients of Non-small Cell Lung Cancer(NSCLC) with carcinomatous pleuritis by the new surgical treatment strategy we have developed .In this study, the efficacy as well as adverseness of this strategy was evaluated. Methods Twenty patients received chemotherapy the intraoperative intrapleural hypotonic cisplatin followed by resection of primary lesion and electrocautery of pleural disseminated nodules. Results There were not increased surgical morbidity and mortality in the twenty patients, nor did mortal postoperative complications or serious adverse events concerning intraoperative chemotherapy occur.The malignant effusion free survival ranged from 2 to 31 months,on average 22 months.The median survival interval was 23 months, and the success rate of control of pleural disease is 100%. The only adverse aspect of this treatment was an increased postoperative drainage volume. Conclusions The reliable and safe surgical treatment may lengthen survival time and improve QOL of the NSCLC patients with carcinomatous pleuritis. At least it deserves to be farther confirmed in furure clinic trials. 　　【Key words】 surgery; non-small cell lung cancer; carcinomatous pleuritis